Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

NCT05775406 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloid Malignancies
Acute Lymphocytic Leukemia
Lymphomas
Advanced Solid Tumors

Interventions

DRUG: KT-253

Sponsor

Kymera Therapeutics, Inc.